A Lilly rep declined to comment to The Post. Tirzepatide, a weekly GLP-1 and GIP drug, produced weight loss of up to 17.8% after 72 weeks. Semaglutide, a weekly GLP-1 drug, caused weight loss of ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

"The View" co-host Whoopi Goldberg addressed a "phony weight loss ad" circulating on Instagram during the show on Wednesday ...

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Looking for a reliable way to lose weight?? Meet Mounjaro UAE, the latest injectable medication that’s making waves among ...

Compared to placebo, the data showed that: Tirzepatide resulted in weight loss of nearly 18% after 72 weeks. Semaglutide produced nearly 14% weight loss after 68 weeks. Retatrutide generated ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

On the basis of the clinical trial data, patients on Zepbound (tirzepatide) 5mg weekly lost 16.1 kg (35.5 lb) on average after 72 weeks. For Zepbound’s 10mg weekly dose, the average weight loss ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...